Occupational Exposure to Pesticides in the Prognosis of Lymphomas
NCT02898870 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 244
Last updated 2017-10-10
Summary
The link between the products of synthetic chemistry and cancer is at the heart of much research. Recent work has identified the use of plant protection agents by farmers as a risk factor for developing non-Hodgkin lymphoma, including diffuse large B cell lymphoma (DLBCL) is the most common histology. Different biological models were used to understand the role of pesticides in lymphomagenesis. To summarize, most pesticides act at the cellular and molecular level, on different signaling pathways. After metabolized by cytochrome P450, these compounds generally become pro-oxidants. The increase in reactive oxygen species rate (SAR) causes the activation of signaling pathways involved in cell proliferation and survival. But deregulation of oxidative status does not in itself justify the specificity of the impact of pesticides on specific pathologies. Several agents have a genotoxic effect, others induce the activation of signaling pathways by binding to transcription factors and others have immunomodulating properties.
Conditions
- Lymphoma Diffuse Large B-cell
Sponsors & Collaborators
-
University Hospital, Montpellier
lead OTHER
Principal Investigators
-
Sylvain LAMURE · University Hospital, Montpellier
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-07-31
- Primary Completion
- 2017-10-31
- Completion
- 2018-04-30
Countries
- France
Study Locations
More Related Trials
-
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
NCT02474550 ·Status: UNKNOWN
-
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
NCT01693614 ·Status: COMPLETED ·Phase: PHASE2
-
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
NCT03104478 ·Status: COMPLETED
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
NCT07078500 ·Status: RECRUITING ·Phase: PHASE2
-
ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma
NCT00169130 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
NCT04113226 ·Status: UNKNOWN ·Phase: PHASE2
-
Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
NCT03850028 ·Status: WITHDRAWN ·Phase: NA
-
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
NCT00498914 ·Status: TERMINATED ·Phase: PHASE2
-
CNS Prophylaxis in Diffuse Large B-cell Lymphoma
NCT02777736 ·Status: UNKNOWN ·Phase: PHASE3
-
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
NCT01359592 ·Status: COMPLETED ·Phase: PHASE2
-
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
NCT05700149 ·Status: RECRUITING
-
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
NCT03681535 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT05338892 ·Status: COMPLETED
-
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
NCT00144807 ·Status: COMPLETED ·Phase: PHASE2
-
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
NCT00008021 ·Status: UNKNOWN ·Phase: PHASE1
-
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
NCT01186978 ·Status: COMPLETED ·Phase: NA
-
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult Participants
NCT05176873 ·Status: COMPLETED ·Phase: PHASE1
-
The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study
NCT05169203 ·Status: COMPLETED
-
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
NCT02285062 ·Status: COMPLETED ·Phase: PHASE3
-
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
NCT05022797 ·Status: TERMINATED ·Phase: PHASE2
-
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
NCT03161223 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
NCT07029217 ·Status: RECRUITING ·Phase: PHASE3
-
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
NCT03298412 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
NCT05459571 ·Status: COMPLETED ·Phase: PHASE2